Literature DB >> 9920782

Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains.

Y Kitamura1, S Shimohama, H Koike, J i Kakimura, Y Matsuoka, Y Nomura, P J Gebicke-Haerter, T Taniguchi.   

Abstract

Recent studies suggest that inflammatory events are associated with plaque formation in the brains of patients with Alzheimer's disease (AD). Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) of these patients appears to slow the progression of disease. We assessed the occurrence of cyclooxygenases (COX-1 and -2) and peroxisome proliferator-activated receptor-gamma (PPARgamma) in temporal cortex from normal and AD brains using specific antibodies. In AD brains, protein levels of COX-1 were increased in both cytosolic and particulate fractions, and COX-2 protein was also increased in the particulate fraction. On the other hand, PPARgamma level was increased in the cytosolic fraction but not in the particulate fraction. Thus, expression levels of COX-1, COX-2, and PPARgamma may change in AD brains. In addition, several NSAIDs which are also PPARgamma activators, such as indomethacin, inhibited COX-2 expression in glial cells. These results suggest that PPARgamma activators have inhibitory effects on inflammatory events in AD brains. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920782     DOI: 10.1006/bbrc.1998.9981

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  52 in total

1.  Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo.

Authors:  M T Heneka; T Klockgether; D L Feinstein
Journal:  J Neurosci       Date:  2000-09-15       Impact factor: 6.167

2.  Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling.

Authors:  Walter J Lukiw
Journal:  Neurochem Res       Date:  2004-06       Impact factor: 3.996

3.  Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists.

Authors:  C K Combs; D E Johnson; J C Karlo; S B Cannady; G E Landreth
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 4.  Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?

Authors:  Kawser Akter; Emily A Lanza; Stephen A Martin; Natalie Myronyuk; Melanie Rua; Robert B Raffa
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

Review 5.  Is there a future for cyclo-oxygenase inhibitors in Alzheimer's disease?

Authors:  Lap Ho; Weiping Qin; Breton S Stetka; Giulio M Pasinetti
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 6.  Neuroimmune nexus of depression and dementia: Shared mechanisms and therapeutic targets.

Authors:  Francis J Herman; Sherry Simkovic; Giulio M Pasinetti
Journal:  Br J Pharmacol       Date:  2019-03-21       Impact factor: 8.739

Review 7.  Therapeutic implications of the prostaglandin pathway in Alzheimer's disease.

Authors:  Eiron Cudaback; Nikolas L Jorstad; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Biochem Pharmacol       Date:  2014-01-13       Impact factor: 5.858

8.  Regulation of brain PPARgamma2 contributes to ketogenic diet anti-seizure efficacy.

Authors:  Timothy A Simeone; Stephanie A Matthews; Kaeli K Samson; Kristina A Simeone
Journal:  Exp Neurol       Date:  2016-08-12       Impact factor: 5.330

9.  Does neuroinflammation fan the flame in neurodegenerative diseases?

Authors:  Tamy C Frank-Cannon; Laura T Alto; Fiona E McAlpine; Malú G Tansey
Journal:  Mol Neurodegener       Date:  2009-11-16       Impact factor: 14.195

10.  Norepinephrine enhances the LPS-induced expression of COX-2 and secretion of PGE2 in primary rat microglia.

Authors:  Johannes C M Schlachetzki; Bernd L Fiebich; Elisabeth Haake; Antonio C P de Oliveira; Eduardo Candelario-Jalil; Michael T Heneka; Michael Hüll
Journal:  J Neuroinflammation       Date:  2010-01-11       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.